Celgene (CELG) Offering Possible 69.49% Return Over the Next 14 Calendar Days

Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $132.00 short put and a strike $127.00 long put offers a potential 69.49% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $132.00 by expiration. The full premium credit of $2.05 would be kept by the premium seller. The risk of $2.95 would be incurred if the stock dropped below the $127.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.

The RSI indicator is at 71.21 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Celgene

How a Conference Caused Bluebird Bio's Shares to Rocket 33% in June
Thu, 06 Jul 2017 02:31:00 +0000
A presentation at the influential American Society of Clinical Oncology in early June fueled optimism in the clinical-stage biotech company.

Celgene to buy BeiGene stake, to develop tumor cancer treatment
Thu, 06 Jul 2017 02:05:49 +0000
Biopharmaceutical company Celgene Corp will buy a stake in BeiGene Ltd and help develop and commercialize BeiGene's investigational treatment for tumor cancers, the companies said on Wednesday. Celgene will acquire 32.7 million, or 5.9 percent of BeiGene's ordinary shares, at $4.58 each, or $59.55 per BeiGene's American Depositary Shares (ADS), they said in a statement.

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers
Thu, 06 Jul 2017 01:00:00 +0000
Celgene Corporation and BeiGene, Ltd. entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia.

FDA puts hold on Merck multiple myeloma trials after deaths
Wed, 05 Jul 2017 21:39:05 +0000
Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy. The rare setback for Keytruda sent Merck shares more than 1 percent lower. Merck has been on a roll with the medicine, jumping to the front of the pack of companies with new immuno-oncology drugs, particularly after Keytruda extended survival as an initial treatment for advanced lung cancer, by far the largest oncology market.

These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan
Wed, 05 Jul 2017 20:12:28 +0000
Here's your Investing Action Plan for Thursday: what you need to know as an investor for the coming day.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.